2022 World Conference on Lung Cancer (ePosters)-EP08.02-080. EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting

EP08.02-080. EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting

Pdf Summary

A real-world study analyzed data from the Flatiron US electronic health records database to examine the testing practices, treatment choices, and clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC). The study included 16,309 patients diagnosed with advanced NSCLC between January 2015 and January 2020. Of these patients, 77% had evidence of an epidermal growth factor receptor (EGFR) test.<br /><br />The study found that almost a quarter of patients with advanced NSCLC did not receive an EGFR test. Among the patients who tested positive for an EGFR mutation and had a result before starting treatment, a quarter of them did not receive an EGFR tyrosine kinase inhibitor (EGFR-TKI) as their first-line treatment. This suggests a need to improve testing implementation so that patients can receive optimal first-line therapy.<br /><br />The use of next-generation sequencing (NGS) for EGFR testing increased over time, with tissue being the most common sample source, although the percentage of tests using blood samples also increased. The median turnaround time from advanced NSCLC diagnosis to receipt of an EGFR test result tended to be shorter in patients who received first-line EGFR-TKIs compared to those who received chemotherapy, immunotherapy, or other treatments at first-line.<br /><br />Patients who received first-line EGFR-TKIs remained on treatment for a longer period before stopping treatment, receiving their next treatment, or experiencing death compared to patients who received other first-line treatments.<br /><br />In conclusion, this real-world analysis highlights the need to improve EGFR testing implementation and reduce turnaround time to ensure that patients with advanced NSCLC receive optimal first-line therapy.

Asset Subtitle

Janakiraman Subramanian

Meta Tag

Speaker Janakiraman Subramanian

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

real-world study

electronic health records

advanced NSCLC

EGFR test

EGFR mutation

first-line treatment

next-generation sequencing

tissue sample

turnaround time

optimal therapy